Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 22Lung Neoplasms 11Brain Neoplasms 4Rare Tumor 1Radiation Pneumonitis 1Non-small Cell Lung Cancer Metastatic 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 1Meningeal Carcinomatosis 1Liver Diseases 1EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor 1Digestive System Diseases 1Carcinoma 1Aumolertinib 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

Pemetrexed 4pembrolizumab 3Carboplatin 3Vinorelbine 2Gemcitabine 2vistusertib 1vandetanib 1spartalizumab 1sotorasib 1sintilimab 1olaparib 1icotinib 1durvalumab 1dacomitinib 1capivasertib 1aumolertinib 1Radiosurgery 1Platinum 1MLN 8237 1Injections 1Immune Checkpoint Inhibitors 1Gefitinib 1GC Temporary Stopping 1Erlotinib Hydrochloride 1Drug Therapy 1Cisplatin 1Bevacizumab 1AZD4547 1AZD 8931 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Non-small Cell Lung Cancer Metastatic × aumolertinib × Clear all
NCT05800223 2023-04-05

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Shanghai Cancer Hospital, China

Phase 3 Recruiting
300 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡